Clinical effects of chemotherapy combined with Bevacizumab and Olaparib in treating advanced ovarian cancer and its effect on serum tumor markers and T-lymphocyte functions

Dan  Liu; Ying  Jiao; Lin  He; Zhifeng Yang

doi:10.12669/pjms.41.6.10843

Dan Liu
Ying Jiao
Lin He
Zhifeng Yang Baoding First Central Hospital

DOI: https://doi.org/10.12669/pjms.41.6.10843

Keywords: bevacizumab, olaparib, combined chemotherapy, advanced ovarian cancer, treatment

Abstract

Objective: To evaluate the clinical efficacy of chemotherapy combined with bevacizumab and olaparib in treating advanced ovarian cancer and investigate the effect of such combination treatment on serum tumor markers and T-lymphocyte function.

Methods: This was a retrospective study. A total of 120 patients with advanced ovarian cancer admitted to Baoding Second Hospital and Baoding First Central Hospital from January 2022 to June 2024 were randomly divided into two groups (n= 60 each group): the control group received standard paclitaxel and carboplatin chemotherapy (TP regimen), while the study group was administered bevacizumab infusions and oral olaparib, in addition to the exact treatment provided for the control group. Comparisons were made between the two groups regarding the clinical efficacy and adverse drug reactions.

Results: The overall response rate was 92% and 68% in the study group and the control group, respectively, suggesting a difference of statistical significance (p=0.00). Furthermore, post-treatment levels of CA153, CA125, CA199, and other markers were significantly lower in the study group than in the control group(all p= 0.00). Meanwhile, the post-treatment levels of CD3+, CD4+, and CD4+/CD8+ were significantly higher in the study group compared to the control group (all p = 0.00). Moreover, the post-treatment levels of TNF-a, CRP, IL-6, and other markers were significantly lower in the study group than in the control group (all p= 0.00).

Conclusion: The combined use of conventional chemotherapy, bevacizumab, and olaparib demonstrates significant clinical efficacy in the treatment of advanced ovarian cancer, which can improve cellular immune function, lower tumor marker levels.

doi: https://doi.org/10.12669/pjms.41.6.10843

How to cite this: Liu D, Jiao Y, He L, Yang Z. Clinical effects of chemotherapy combined with Bevacizumab and Olaparib in treating advanced ovarian cancer and its effect on serum tumor markers and T-lymphocyte functions. Pak J Med Sci. 2025;41(6):1572-1578. doi: https://doi.org/10.12669/pjms.41.6.10843

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.